DermTech (DMTK) Misses Q1 EPS by 13c

DermTech (NASDAQ: DMTK) reported Q1 EPS of ($0.55), $0.13 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $2.52 million versus the consensus estimate of $2.11 million.

Second Quarter 2021 Guidance:

Management estimates that second quarter 2021 assay revenue will be between $2.4 million and $2.8 million.

For earnings history and earnings-related data on DermTech (DMTK) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Knight Transportation (KNX) PT Raised to $85 at Stifel Ahead of Q2 Earnings